Lifecore Biomedical reported second quarter 2026 revenues of $34.2 million, a 6.2% decrease from the prior year period, and a net loss of $6.2 million ($0.19 per diluted share). For the six months ended June 30, 2026, revenues were $57.4 million, down 19.9%, with a net loss of $21.1 million ($0.61 per diluted share). Adjusted EBITDA was $8.6 million for the quarter and $9.6 million for the six-month period. The company reaffirmed its full-year 2026 revenue guidance of $120–$125 million and Adjusted EBITDA guidance of $20.5–$25 million. Lifecore added 13 new programs to its pipeline over the last 12 months, including eight late-stage projects, and ended the quarter with approximately $38.8 million in liquidity. The company operates as a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceuticals and hyaluronic acid.

Lifecore Biomedical, Inc. announced that holders of all 49,263 outstanding shares of Series A Redeemable Convertible Preferred Stock received redemption notices, requiring a total payment of approximately $52.1 million. The company must pay the redemption amounts 180 days after notice, with a deadline of December 28, 2026, and must obtain lender consent to facilitate the payments. Lifecore Biomedical, Inc. is a medical device and pharmaceutical manufacturing company.